| Wang, Ruoyu NA |
NCT07003074: A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 642 | RoW | TQB2102 for Injection, Docetaxel combined + Trastuzumab +Pertuzumab | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Breast Cancer | 07/29 | 07/30 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Active, not recruiting | 3 | 8000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients with Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 83 | RoW | GT101 injection, Gemcitabine injection | Grit Biotechnology | Adult | 01/27 | 01/27 | | |
NCT07367529: A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection |
|
|
| Not yet recruiting | 1/2 | 465 | RoW | TQB6411 for Injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Lung Cancer | 12/28 | 12/28 | | |
| Recruiting | 1 | 150 | RoW | TQB2922 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Cancer | 12/26 | 12/27 | | |
NCT07205198: A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects. |
|
|
| Recruiting | 1 | 160 | RoW | SIBP-A10 | Shanghai Institute Of Biological Products | Advanced Tumors | 12/28 | 12/28 | | |
